Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
2.84% $3.98
America/New_York / 28 mar 2024 @ 11:36
FUNDAMENTALS | |
---|---|
MarketCap: | 7.03 mill |
EPS: | -88.80 |
P/E: | -0.0400 |
Earnings Date: | Mar 28, 2024 |
SharesOutstanding: | 1.766 mill |
Avg Daily Volume: | 0.355 mill |
RATING 2024-03-27 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | |||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0400 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -0.0400 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.894 (-77.53%) $-3.09 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 2.81 - 5.18 ( +/- 29.70%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-11 | Hoffman Lawrence R | Sell | 0 | Common Stock |
2022-09-21 | Rich Stuart | Buy | 1 909 585 | Common Stock |
2022-09-21 | Rich Stuart | Sell | 1 909 585 | Common Stock |
2022-08-11 | Doogan Declan | Sell | 567 871 | Common Stock |
2022-06-09 | Rich Stuart | Buy | 100 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
31.16 |
Last 92 transactions |
Buy: 35 341 052 | Sell: 26 670 670 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.98 (2.84% ) |
Volume | 0.0382 mill |
Avg. Vol. | 0.355 mill |
% of Avg. Vol | 10.76 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.11 | N/A | Active |
---|
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.